BACKGROUND: Currently, there is little knowledge concerning expression of metallothionein-III (MT-III), also known as growth-inhibitory factor, in non-small cell lung cancer (NSCLC). MATERIALS AND METHODS: In this study, we evaluated MT-III expression in 184 patients using immunohistochemistry and in 61 cases using real-time polymerase chain reaction. RESULTS: MT-III mRNA expression was significantly higher in NSCLC as compared to non-malignant lung tissues (NMLT; p<0.0086). MT-III expression was noted in the cytoplasm and nucleus of cancer cells. Significantly lower nuclear MT-III (p<0.0001) expression and significantly higher cytoplasmic MT-III (p=0.0068) expression was noted in the pneumocytes of NMLT, as compared to NSCLC. Nuclear MT-III expression was significantly higher in G1 cases as compared to G2 (p=0.0308) and G3 (p=0.0194) cases. Low cytoplasmic MT-III expression was associated with larger primary tumour size (p=0.0378). Lower MT-III mRNA and cytoplasmic MT-III expression was associated with poor patient outcome (p=0.0410 and p=0.0347, respectively). CONCLUSION: MT-III expression may have an impact on the pathogenesis of NSCLC.
BACKGROUND: Currently, there is little knowledge concerning expression of metallothionein-III (MT-III), also known as growth-inhibitory factor, in non-small cell lung cancer (NSCLC). MATERIALS AND METHODS: In this study, we evaluated MT-III expression in 184 patients using immunohistochemistry and in 61 cases using real-time polymerase chain reaction. RESULTS:MT-III mRNA expression was significantly higher in NSCLC as compared to non-malignant lung tissues (NMLT; p<0.0086). MT-III expression was noted in the cytoplasm and nucleus of cancer cells. Significantly lower nuclear MT-III (p<0.0001) expression and significantly higher cytoplasmic MT-III (p=0.0068) expression was noted in the pneumocytes of NMLT, as compared to NSCLC. Nuclear MT-III expression was significantly higher in G1 cases as compared to G2 (p=0.0308) and G3 (p=0.0194) cases. Low cytoplasmic MT-III expression was associated with larger primary tumour size (p=0.0378). Lower MT-III mRNA and cytoplasmic MT-III expression was associated with poor patient outcome (p=0.0410 and p=0.0347, respectively). CONCLUSION:MT-III expression may have an impact on the pathogenesis of NSCLC.
Authors: Ryan P Lange; Allen Everett; Pratima Dulloor; Frederick K Korley; Chetan Bettegowda; Cherie Blair; Stuart A Grossman; Matthias Holdhoff Journal: Cancer Invest Date: 2014-07-14 Impact factor: 2.176
Authors: Alicja M Kmiecik; Bartosz Pula; Jaroslaw Suchanski; Mateusz Olbromski; Agnieszka Gomulkiewicz; Tomasz Owczarek; Anna Kruczak; Aleksandra Ambicka; Janusz Rys; Maciej Ugorski; Marzena Podhorska-Okolow; Piotr Dziegiel Journal: PLoS One Date: 2015-05-01 Impact factor: 3.240
Authors: Wen Cai Zhang; Tan Min Chin; Henry Yang; Min En Nga; Declan Patrick Lunny; Edwin Kok Hao Lim; Li Li Sun; Yin Huei Pang; Yi Ning Leow; Shanneen Rossellini Y Malusay; Priscilla Xin Hui Lim; Jeravan Zili Lee; Benedict Jian Wei Tan; Ng Shyh-Chang; Elaine Hsuen Lim; Wan Teck Lim; Daniel Shao Weng Tan; Eng Huat Tan; Bee Choo Tai; Ross Andrew Soo; Wai Leong Tam; Bing Lim Journal: Nat Commun Date: 2016-06-21 Impact factor: 14.919
Authors: Miguel Angel Merlos Rodrigo; Hana Michalkova; Vladislav Strmiska; Berta Casar; Piero Crespo; Vivian de Los Rios; J Ignacio Casal; Yazan Haddad; Roman Guran; Tomas Eckschlager; Petra Pokorna; Zbynek Heger; Vojtech Adam Journal: Sci Rep Date: 2021-03-09 Impact factor: 4.379
Authors: Bartosz Pula; Tadeusz Tazbierski; Aleksandra Zamirska; Bozena Werynska; Andrzej Bieniek; Jacek Szepietowski; Janusz Rys; Piotr Dziegiel; Marzena Podhorska-Okolow Journal: Pathol Oncol Res Date: 2015-01 Impact factor: 3.201